Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells

Cancer Letters

Volumn 295, Issue 1, 2010, Pages 110-123

  Wang, Yue ^a,b   Niu, Xiu Long ^a   Qu, Ye ^a   Wu, Jian ^a   Zhu, Ya Qin ^a   Sun, Wei Jia ^a   Li, Ling Zhi ^a,b  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard   (China)

Author keywords

Apoptosis inhibitory proteins; Chemoresistance; Interleukin 6 (IL 6); Multidrug resistance related genes; Ovarian cancer

Indexed keywords

CASPASE 3; CISPLATIN; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; RAS PROTEIN; RECOMBINANT INTERLEUKIN 6; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; CELL LINE, TUMOR; CISPLATIN; CYTOKINE RECEPTOR GP130; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; INTERLEUKIN-6; MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RAF KINASES; RAS PROTEINS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 77953611991     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.02.019     Document Type: Article

References (59)

1. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3:502-516.
2. Richardson A., Kaye S.B. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist. Updates 2005, 8:311-321.
3. Sehgal P.B., Wang L., Rayanade R., Pan H., Margulies L. Interleukin-6-type cytokines. Ann. NY. Acad. Sci. 1995, 762:1-14.
4. Hong D.S., Angelo L.S., Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007, 110:1911-1928.
5. Hardin J., MacLeod S., Grigorieva I., Chang R., Barlogie B., Xiao H., Epstein J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994, 84:3063-3070.
6. Chauhan D., Kharbanda S., Ogata A., Urashima M., Teoh G., Robertson M., Kufe D.W., Anderson K.C. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997, 89:227-234.
7. Mizutani Y., Bonavida B., Koishihara Y., Akamatsu K., Ohsugi Y., Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995, 55:590-596.
8. Gores G.J. Cholangiocarcinoma: current concepts and insights. Hepatology 2003, 37:961-969.
9. Borsellino N., Belldegrun A., Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995, 55:4633-4639.
10. Hobisch A., Ramoner R., Fuchs D., Godoy-Tundidor S., Bartsch G., Klocker H., Culig Z. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin. Cancer Res. 2001, 7:2941-2948.
11. Pu Y.S., Hour T.C., Chuang S.E., Cheng A.L., Lai M.K., Kuo M.L. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 2004, 60:120-129.
12. Conze D., Weiss L., Regen P.S., Bhushan A., Weaver D., Johnson P., Rincón M. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001, 61:8851-8858.
13. Plante M., Rubin S.C., Wong G.Y., Federici M.G., Finstad C.L., Gastl G.A. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994, 73:1882-1888.
14. Scambia G., Testa U., Panici P.B., Martucci R., Foti E., Petrini M., Amoroso M., Masciullo V., Peschle C., Mancuso S. Interleukin-6 serum levels in patients with gynecological tumors. Int. J. Cancer 1994, 57:318-323.
15. Tempfer C., Zeisler H., Sliutz G., Haeusler G., Hanzal E., Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol. Oncol. 1997, 66:27-30.
16. Scambia G., Testa U., Benedetti P., Foti E., Martucci R., Gadducci A., Perillo A., Facchini V., Peschle C., Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Brit. J. Cancer 1995, 71:354-356.
17. Penson R.T., Kronish K., Duan Z., Feller A.J., Stark P., Cook S.E., Duska L.R., Fuller A.F., Goodman A.K., Nikrui N., MacNeill K.M., Matulonis U.A., Preffer F.I., Seiden M.V. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int. J. Gynecol. Cancer 2000, 10:33-41.
18. Obata N.H., Tamakoshi K., Shibata K., Kikkawa F., Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res. 1997, 17:337-342.
19. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005, 65:10794-10800.
20. Rabinovich A., Medina L., Piura B., Segal S., Huleihel M. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res. 2007, 27:267-272.
21. Wang Y., Yang J., Gao Y., Dong L.J., Liu S., Yao Z. Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma. Cancer Biol. Ther. 2007, 6:864-871.
22. Yang J., Wang Y., Gao Y., Shao J., Zhang X.J., Yao Z. Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer. Cytokine 2009, 46:382-391.
23. Duan Z., Feller A.J., Penson R.T., Chabner B.A., Seiden M.V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin. Cancer Res. 1999, 5:3445-3453.
24. Hirano T., Nakajima K., Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 1997, 8:241-252.
25. Hayakawa J., Ohmichi M., Kurachi H., Ikegami H., Kimura A., Matsuoka T., Jikihara H., Mercola D., Murata Y. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem. 1999, 274:31648-31654.
26. Persons D.L., Yazlovitskaya E.M., Cui W., Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res. 1999, 5:1007-1014.
27. Lee S., Yoon S., Kim D.H. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells. Gynecol. Oncol. 2007, 104:338-344.
28. Hayakawa J., Ohmichi M., Kurachi H., Kanda Y., Hisamoto K., Nishio Y., Adachi K., Tasaka K., Kanzaki T., Murata Y. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000, 60:5988-5994.
29. Mabuchi S., Ohmichi M., Kimura A., Hisamoto K., Hayakawa J., Nishio Y., Adachi K., Takahashi K., Arimoto-Ishida E., Nakatsuji Y., Tasaka K., Murata Y. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J. Biol. Chem. 2002, 277:33490-33500.
30. Ohta T., Ohmichi M., Hayasaka T., Mabuchi S., Saitoh M., Kawagoe J., Takahashi K., Igarashi H., Du B., Doshida M., Mirei I.G., Motoyama T., Tasaka K., Kurachi H. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 2006, 147:1761-1769.
31. Hu L., Hofmann J., Lu Y., Mills G.B., Jaffe R.B. Inhibition of phosphatidylinositol 3-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002, 62:1087-1092.
32. Eliopoulos A.G., Kerr D.J., Herrod J., Hodgkins L., Krajewski S., Reed J.C., Lawrence S.Y. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995, 11:1217-1228.
33. Williams J., Lucas P.C., Griffith K.A., Choi M., Fogoros S., Hu Y.Y., Liu J.R. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol. Oncol. 2005, 96:287-295.
34. Li J., Feng Q., Kim J.M., Schneiderman D., Liston P., Li M., Vanderhyden B., Faught W., Fung M.F., Senterman M., Korneluk R.G., Tsang B.K. Human ovarian cancer and cisplatin resistance. possible role of inhibitor of apoptosis proteins. Endocrinology 2001, 142:370-380.
35. Sasaki H., Sheng Y., Kotsuji F., Tsang B.K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000, 60:5659-5666.
36. Syed V., linski G., Mok S.C., Ho S.M. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J. Natl. Cancer Inst. 2002, 94:617-629.
37. Hayakawa J., Ohmichi M., Kurachi H., Ikegami H., Kimura A., Matsuoka T., Jikihara H., Mercola D., Murata Y. Inhibition of extracellular signal regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem. 1999, 274:31648-31654.
38. Asschert J.G., Vellenga E., Ruiters M.H., de Vries E.G. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int. J. Cancer 1999, 82:244-249.
39. Duan Z., Lamendola D.E., Penson R.T., Kronish K.M., Seiden M.V. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine 2002, 17:234-242.
40. Baekelandt M.M., Holm R., Nesland J.M., Tropé C.G., Kristensen G.B. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 2000, 20:1061-1067.
41. Goff B.A., Paley P.J., Greer B.E., Gown A.M. Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol. Oncol. 2001, 81:18-24.
42. Yakirevich E., Sabo E., Naroditsky I., Sova Y., Lavie O., Resnick M.B. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol. Oncol. 2006, 100:152-159.
43. Schisselbauer J.C., Hogan W.M., Buetow K.H., Tew K.D. Heterogeneity of glutathione S-transferase enzyme and gene expression in ovarian carcinoma. Pharmacogenetics 1992, 2:63-72.
44. Lewis A.D., Hayes J.D., Wole C.R. Glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance. intrinsic differences and cell cycle effects. Carcinogenesis 1998, 9:1283-1287.
45. Awasthi S., Sharma R., Singhal S.S., Herzog N.K., Chaubey M., Awasthi Y.C. Modulation of cisplatin cytotoxicity by sulphasalazine. Brit. J. Cancer 1994, 70:190-194.
46. Zhang T., Guan M., Jin H.Y., Lu Y. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Gynecol. Oncol. 2005, 97:501-507.
47. Raffo A.J., Perlman H., Chen M.W., Day M.L., Streitman J.S., Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995, 55:4438-4445.
48. Schwarze M.M., Hawley R.G. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin-6-mediated upregulation of bcl-xL. Cancer Res. 1995, 55:2262-2265.
49. Lin M.T., Juan C.Y., Chang K.J., Chen W.J., Kuo M.L. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis 2001, 22:1947-1953.
50. Yamagiwa Y., Marienfeld C., Meng F., Holcik M., Patel T. Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res. 2004, 64:1293-1298.
51. Arimoto-Ishida E., Ohmichi M., Mabuchi S., Takahashi T., Ohshima C., Hay-akawa J., Kimura A., Takahashi K., Nishio Y., Sakata M., Kurachi H., Tasaka K., Murata Y. Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin. Endocrinology 2004, 145:2014-2022.
52. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., Saito M., Kawagoe J., Takahashi K., Yada-Hashimoto N., Sakata M., Motoyama T., Ku-rachi H., Tasaka K., Murata Y. Inhibition of NFkB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J. Biol. Chem. 2004, 279:23477-23485.
53. Duan Z., Foster R., Bell D.A., Mahoney J., Wolak K., Vaidya A., Hampel C., Lee H., Seiden M.V. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res. 2006, 12:5055-5063.
54. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
55. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
56. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
57. George J.A., Chen T., Taylor C.C. SRC tyrosine kinase and multidrug resistance protein-1inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res. 2005, 65:10381-10388.
58. Savarese T.M., Campbell C.L., McQuain C., Mitchell K., Guardiani R., Quesenberry P.J., Nelson B.E. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. Cytokine 2002, 17:324-334.
59. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., Nam S., Eweis I., Diaz N., Sullivan D., Yoder S., Enkemann S., Eschrich S., Lee J.H., Beam C.A., Cheng J., Minton S., Muro-Cacho C.A., Jove R. Persistent activation of stat3 signaling induces surviving gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer. Res. 2006, 12:11-19.